Molecular Health GmbH
Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL
DGAP-News: Molecular Health GmbH / Key word(s): Agreement/Agreement
Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL – Molecular Health Predict enables highly accurate estimates of clinical trial success probabilities – Exclusive license for the financial industry granted to DATEN CAPITAL – Molecular Health to receive an annual license fee and success-based payments
Heidelberg, Germany and Boston, MA – Monday, January 7, 2019 – Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome(R), is pleased to announce that it has granted an exclusive license for Molecular Health Predict (MH Predict) to DATEN CAPITAL LLP (DATEN), for its use in the financial industry. MH Predict was developed by Molecular Health to calculate the likelihood of success of drug clinical trials, and DATEN is a private limited liability partnership founded to commercialize data-science, AI-driven approaches to investing. Molecular Health will receive an annual license fee as well as success-based payments from DATEN. Friedrich von Bohlen, PhD, Co-founder & CEO of Molecular Health GmbH, said: “We are very excited to announce this exclusive license for the financial industry with DATEN CAPITAL. Understanding and effectively predicting the likelihood of success of clinical trials is critical to achieving better efficiencies and savings in drug R&D – which today still represents billions of dollars of annual losses due to trial attrition for both pharmaceutical companies and investors. We believe that MH Predict will drive a true paradigm shift in drug development, resource and investment allocations and ultimately patient outcomes. We look forward to launching this product also to the pharmaceutical industry in early 2019.” “I came to know Friedrich von Bohlen and Molecular Health during my time in investment banking at Goldman Sachs. After learning more about the company, and assessing its technology, I became increasingly convinced of the potential for Molecular Health to transform the drug development industry. Our mission when founding DATEN CAPITAL was to build a data-science, AI-driven approach to allocating capital. This is why we are particularly excited to have obtained an exclusive license to apply MH Predict to the financial markets. Our aim, and our belief, is that we will help enable the biopharmaceutical industry to deliver new drugs to the market in a much better, faster and cheaper way,” said Amit R. Karna, CFA, Managing Partner at DATEN CAPITAL LLP.
About Molecular Health About DATEN CAPITAL
Related Links
07.01.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |